News

Welcome to the fortnightly Health Improvement and Innovation Digest. The Digest has links to key evidence of interest, with access to new content arranged by topic. You can forward this newsletter to others who may be interested in receiving it. They can register and subscribe here . You can also access other recent issues of the digest here. If you have any queries, please email us at  library@health.govt.nz . Thank you for reading the Health Improvement and Innovation Digest this year. Our...

People in New Zealand aspire to have a health care system that delivers world-class cancer care; a system that provides timely access to high-quality services designed around their specific needs and those of their whānau. Te Aho o Te Kahu | Cancer Control Agency undertakes national initiatives to improve cancer outcomes for people in New Zealand and to assemble and disseminate cancer data and information to inform decision-making and service delivery.  As part of our ongoing work to provide...

​

As we come to the end of 2025, we want to thank you for being part of an extraordinary year. Together with your peers, you contributed to 25,000 webinar registrations, 60,000 podcast downloads, and 12,000 eLearning starts. In 2026, we’re committed to bringing you even more premium content created to empower primary care professionals. And we’re starting as we mean to go on, with:  Adult ADHD: From diagnosis to long-term management WEBINAR 3 February, 7.30pm: Join Psychiatrist David Codyre who...

Below is the latest information on Pharmac consultations, notifications, and supply issues for Primary Care Prescribers for week 05 December 2025. It includes information on:  New updates Resolved Supply Issues Pharmac funding both Estradot and Estradiol TDP Mylan brands of oestradiol patches From 1 December 2025, the funded brands of oestradiol patches will be Estradiol TDP Mylan and Estradot. Everyone who uses funded oestradiol patches will need to use either of these brands. Pharmac have...

We are writing to remind you of the delist (no longer funded) date of the 10mg presentations of clomipramine (capsules and tablets). Key Points: •          The delist date from the Pharmaceutical Schedule is 1 April 2026 •          Clomipramine 25mg presentations will remain available and listed on the Pharmaceutical Schedule •           Please continue to consider alternative options for patients that require the lower 10mg dose   Please share this information with...